Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma

RegulatoryNegative

AI Analysis

Summary

Novo Nordisk is seeking an injunction to halt allegedly misleading obesity drug advertisements from Eli Lilly, while J&J reinforces its position in multiple myeloma. The FDA has begun reviewing a highly anticipated medicine.

Outcome Details

FDA began reviewing a highly anticipated medicine

Importance:4/10

Sentiment:

-0.30

litigationadvertisingobesitymultiple myelomaFDA reviewcompetitive dynamics

Related Companies

$NVO $LLY

Read the original article

Published by BioPharma Dive on July 24, 2026 1:00 PM

Read Original